Immunovant Shifts Focus from Batoclimab to IMVT-1402
Immunovant, the biotech company behind batoclimab, will continue to prioritize its next-gen asset, IMVT-1402, over the chronic autoimmune disorder treatment. The decision comes after a Phase III trial of batoclimab showed promise in improving aspects of daily living for patients with myasthenia gravis. The data from the trial revealed significant improvements for patients taking high … Read more